Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.
Npj Precision Oncology
Cleary, James M JM; Rouaisnel, Betty B; Daina, Antoine A; Raghavan, Srivatsan S; Roller, Lauren A LA; Huffman, Brandon M BM; Singh, Harshabad H; Wen, Patrick Y PY; Bardeesy, Nabeel N; Zoete, Vincent V; Wolpin, Brian M BM; Losman, Julie-Aurore JA
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
Blood Advances
Chifotides, Helen T HT; Masarova, Lucia L; Alfayez, Mansour M; Daver, Naval N; Alvarado, Yesid Y; Jabbour, Elias E; Konopleva, Marina M; Kantarjian, Hagop M HM; Patel, Keyur P KP; DiNardo, Courtney D CD; Verstovsek, Srdan S
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
The Lancet. Gastroenterology & Hepatology
Lowery, Maeve A MA; Burris, Howard A HA; Janku, Filip F; Shroff, Rachna T RT; Cleary, James M JM; Azad, Nilofer S NS; Goyal, Lipika L; Maher, Elizabeth A EA; Gore, Lia L; Hollebecque, Antoine A; Beeram, Muralidhar M; Trent, Jonathan C JC; Jiang, Liewen L; Fan, Bin B; Aguado-Fraile, Elia E; Choe, Sung S; Wu, Bin B; Gliser, Camelia C; Agresta, Samuel V SV; Pandya, Shuchi S SS; Zhu, Andrew X AX; Abou-Alfa, Ghassan K GK
Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
Asian Pacific Journal Of Cancer Prevention : Apjcp
Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.